Liquid Biopsy | December Round-Up 2024

Highlights & Summary

Liquid Biopsy (LBx) continued to develop through December, featuring many collaborations and some clinical trial updates.

?

Clinical and Regulatory

Personalis and Tempus expanded their commercial relationship, offering Personalis’ NeXT Personal MRD to biopharma through Tempus, allowing bundling of MRD with Tempus’ other offerings. Guardant Health and Boehringer Ingelheim announced a collaboration to pursue approval of Guardant360 CDx as a companion diagnostic for zongertinib, a TKI inhibitor that selectively inhibits HER2 while sparing EGFR in NSCLC. Tracer Biotechnologies announced a multi-year project with AstraZeneca, enabling AstraZeneca to use Tracer’s ctDNA monitoring technology based on dPCR for clinical trials. Guardant Health and COTA partner to offer a combination of COTA’s EHR data and Guardant’s clinicogenomic testing data to biopharmaceutical researchers. PanGIA Biotech announced a collaboration with Canary Oncoceutics to introduce PanGIA Prostate Assay, an AI-integrated urine-based liquid biopsy test, to India.

1 | Personalis, Tempus Expand MRD Diagnostics Partnership to Include Biopharma MRD Partnership | Personalis, Tempus ?

2 | Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer CDx Collaboration | Guardant Health, Boehringer Ingelheim

3 | Tracer Biotechnologies Announces Agreement for Next-Generation Cancer Monitoring for Drug Development Multi-Year Project | Tracer Biotechnologies, AstraZeneca

Clinical Trials & Study Results

Foresight Diagnostics announced the launch of SHORTEN-ctDNA to evaluate Foresight CLARITY MRD’s ability to enable real-time treatment optimization for patients with DLBCL, investigating whether patients with early clearance of ctDNA can receive fewer cycles of chemotherapy while maintaining survival outcomes. Natera announced enrollment of first patients in SAGITTARIUS, a randomized, phase III clinical trial in colon cancer evaluating Signatera’s use for guiding personalized adjuvant treatment. ?

1 | Foresight Diagnostics Announces Launch of SHORTEN-ctDNA Trial to Evaluate Personalized Treatment Duration in DLBCL Lymphoma Patients Trial Launch | Foresight Diagnostics

2 | Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer Trial Enrollment | Natera

?

Additional Sources

Company Announcements & Product Launches

1 | COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics Partnership | COTA, Guardant Health

2 | PanGIA Biotech Announces Landmark Partnership Agreement for First Liquid Biopsy Prostate Cancer Assay in India Partnership | PanGIA Biotech, Canary Oncoceutics